A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib

ConclusionThe successful modeling exercise of erdafitinib preclinical data showed how translational PK-PD modeling might be a tool to help to inform the choice of the doses in FIH studies.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research